Anti-IL-6 Domain Antibodies With Fatty Acids for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for cardiovascular disease (CVD) targeting IL-6 have limitations such as high production costs, immunogenicity, and off-target effects, necessitating the development of novel compounds with improved bioavailability, stability, and specificity for effective treatment.
Innovation Solution
Development of anti-IL-6 compounds, particularly immunoglobulin single variable domain (ISVD) molecules with engineered features like C-terminal extensions and substituents, enabling oral and parenteral administration, and prolonged half-life, suitable for clinical scale manufacturing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to block IL-6 receptor, then therapeutic efficacy is improved, but production costs increase and immunogenicity occurs
Solution Approach 1:
The patent extracts and utilizes only the essential antigen-binding domain (single variable domain) from the complete monoclonal antibody structure. This extracted domain retains the ability to bind IL-6 with high affinity and specificity while eliminating the need for complex antibody production processes, thereby reducing manufacturing costs and production time while maintaining therapeutic efficacy.
Solution Approach 2:
The single variable domain antibody fragment serves as a simplified, more economical alternative to full-length monoclonal antibodies. While having a shorter half-life that requires more frequent administration, it provides cost-effective therapy with reduced production complexity and lower manufacturing costs compared to conventional monoclonal antibodies.
2Reliability
If monoclonal antibodies are used to block IL-6 receptor, then therapeutic efficacy is improved, but immunogenicity increases
Solution Approach 1:
By extracting only the variable domain that contains the antigen-binding site, the patent eliminates the constant regions of the antibody that are primarily responsible for immunogenicity. This minimal structure retains therapeutic efficacy through specific IL-6 binding while significantly reducing the risk of immune response against the therapeutic agent itself.
3Ease of manufacture
If small molecule inhibitors are used to target IL-6 signaling, then production costs are reduced, but off-target effects increase
Solution Approach 1:
The single variable domain antibody is engineered with highly specific local binding properties through its complementarity-determining regions (CDRs) that are precisely selected to recognize and bind only to the IL-6 antigen. This localized specificity at the molecular binding interface ensures high target selectivity while maintaining the simplicity and low production cost advantages of protein-based therapeutics over conventional small molecules.
4Reliability
If conventional antibodies are administered, then therapeutic effect is achieved, but administration route is limited to parenteral
Solution Approach 1:
The patent modifies key parameters of the antibody molecule by using a single variable domain format instead of full-length antibody, which changes the molecular size, stability, and absorption characteristics. These parameter changes enable the therapeutic to achieve sufficient stability and bioavailability for oral administration while maintaining its ability to bind IL-6 and produce therapeutic effects, thus expanding administration routes beyond parenteral injection.
Data Source
AI summary
The present invention relates to compounds (e.g. ISVDs, polypeptides, polypeptide derivatives) capable of binding to Interleukin-6 (IL-6) and their use in the treatment of inflammatory diseases such as, e.g. cardiovascular disease (CVD).